Senapati J, Abuasab T, Haddad FG, Ravandi F, et al. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 2022 Dec 24. doi: 10.1002/ajh.26811.
PMID: 36565294